Optimal platelet inhibition in patients undergoing PCI: Data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study

American Heart Journal

Volumn 154, Issue 2, 2007, Pages 344.e1-344.e5

  Mardikar, H M ^a   Hiremath, M S ^b   Moliterno, David J ^c   Mathew, Rony ^d   Arora, Rangolee ^a   Deo, Dhananjay ^a   Hiremath, J S ^b   Deshpande, N V ^a   Khan, Aziz ^a   Joseph, Jacob ^d   Mukherjee, Debabrata ^c  

^a Spandan Heart Institute ^*  (India)

^b Ruby Hall Clinic ^*  (India)

^c UNIVERSITY OF KENTUCKY   (United States)

^d Lisie Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34447511289     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.05.007     Document Type: Article

References (16)

1. Davies M.J. Pathology of arterial thrombosis. Br Med Bull 50 (1994) 789-802
2. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) 156-175
3. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
4. Topol E.J. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 97 (1998) 211-218
5. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 36 (2000) 970-1062
6. Kereiakes D.J., Lorenz T., Young J.J., et al. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thromb Thrombolysis 12 (2001) 123-127
7. Simon D.I., Liu C.B., Ganz P., et al. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Catheter Cardiovasc Interv 52 (2001) 425-432
8. Lakkis N.M., George S., Thomas E., et al. Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors. Catheter Cardiovasc Interv 53 (2001) 346-351
9. Danzi G.B., Capuano C., Sesana M., et al. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention. Am J Cardiol 97 (2006) 489-493
10. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103 (2001) 2572-2578
11. Batchelor W.B., Tolleson T.R., Huang Y., et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 106 (2002) 1470-1476
12. Gilchrist I.C., O'Shea J.C., Kosoglou T., et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 104 (2001) 406-411
13. Valgimigli M., Percoco G., Barbieri D., et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 44 (2004) 14-19
14. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
15. Gurbel P.A., Bliden K.P., Hayes K.M., et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 (2005) 1392-1396
16. Behan M.W., Fox S.C., Heptinstall S., et al. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets 16 (2005) 73-80